ClinicLens specialt
139 items automatically indexed in this specialt.
← Back to all specialtiesOncology
Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter random
Open articleOncology
peripherally inserted central catheters (PICCs) and totally implantable ports (Ports) are used for chemotherapy administration. This study aimed to compare their morbidity, mortality, and complication rates. a prospective, randomised, comparative single-centre study with 6 months
Open articleOncology
The increasing incidence of cancer and the fact that the family is an important factor in cancer care; attention to the positive mental health of cancer patients should be sought to provide solutions to improve the mental health of these caregivers. The present study aimed to inv
Open articleOncology
People impacted by cancer may be confronted with conflicting and misleading cancer-related information that is everywhere in daily life. The Informed Health Choices-Cancer (IHC-C) programme was developed to equip participants with the skills and knowledge necessary to think criti
Open articleOncology
New England Journal of Medicine, Volume 395, Issue 5, Page 427-439, July 30, 2026.
Open articleOncology
New England Journal of Medicine, Volume 395, Issue 5, Page 517-518, July 30, 2026.
Open articleOncology
New England Journal of Medicine, Volume 395, Issue 5, Page 503-505, July 30, 2026.
Open articleOncology
New England Journal of Medicine, Ahead of Print.
Open articleOncology
New England Journal of Medicine, Ahead of Print.
Open articleOncology
We read with interest the Article1 by Claudia Allemani and colleagues, which provides a landmark contribution to global cancer surveillance. Nevertheless, we have concerns regarding the representativeness of the Cancer Survival Index reported for Colombia: 72·7% for all cancers a
Open articleOncology
We welcome the comments from Oscar Ramirez and colleagues, regarding the hospital-based surveillance system (VIGICANCER1) that includes 55–60% of Colombian children diagnosed with cancer. As VIGICANCER is not a population-based cancer registry (PBCR), it was not invited to contri
Open articleOncology
The TORPEdO trial1 represents a landmark contribution to oropharyngeal cancer management, demonstrating similar late quality-of-life outcomes between intensity-modulated proton therapy (IMPT) and intensity-modulated radiotherapy (IMRT). However, as head and neck surgeons involved
Open articleOncology
We thank Pietro De Luca and colleagues for their thoughtful letter and agree that surgical salvage after intensity-modulated proton therapy (IMPT) is an important and underexplored question.
Open articleOncology
We had just reviewed how the lymph node biopsy would be performed when I asked the study volunteer why he wanted to do it. Did he understand there would be no direct benefit, that the results were not going to improve his health? There were also risks involved, such as pain, blee
Open articleOncology
In contemporary management of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, it is standard to switch therapies at tumour progression, defined by RECIST criteria in clinical trials, and by other measures (many, ironically, considered non-measurab
Open articleOncology
The recently reported SUPREMO trial evaluated chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. Although chest wall radiotherapy did not improve overall survival, local recurrence was reduced (hazard ratio [HR] 0·45 [95%CI 0·20 to 0·99]),
Open articleOncology
Randomised trials in rare cancers are scarce, and those that achieve adequate enrolment and methodological rigour warrant recognition. Upper tract urothelial carcinoma, which comprises only 5–10% of urothelial malignancies, presents unique challenges for trialists because of its
Open articleOncology
For patients with high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, therapeutic decision making remains challenging. Radical cystectomy offers the most reliable oncological control, but at the cost of major surgery, urinary diversion, and las
Open articleOncology
Radioactive iodine-refractory differentiated thyroid cancer remains a therapeutically challenging disease despite important advances over the last decade. Multi-kinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) signaling have improved progression-fre
Open articleOncology
Preoperative fluoropyrimidine-based chemoradiotherapy constituted the cornerstone in the management of locally advanced rectal cancer for more than two decades. Randomised trials established chemoradiotherapy followed by total mesorectal excision surgery as a standard approach, i
Open articleOncology
Gastric cancer remains a major cause of cancer mortality, and prognosis is particularly poor in individuals with peritoneal metastases.1,2 Although the integration of immunotherapy and targeted agents—such as trastuzumab or zolbetuximab—into systemic chemotherapy has improved sur
Open articleOncology
In a post-hoc analysis of the PACIFIC trial published in The Lancet Oncology, Leonardo Brunetti and colleagues1 found that baseline proton pump inhibitor and antibiotic use was associated with worse progression-free survival in patients with stage III non-small-cell lung cancer (
Open articleOncology
Ward and colleagues1 offer a sophisticated simulation of 17 cancer typesacross 200 countries. The authors’ projections of persistent survival disparities are likely correct in direction (ie, Africa and Asia have lowest survival, North America and Oceania have highest survival). H
Open articleOncology
We thank Atif Kamal for his engagement and agree that investment in population-based cancer registries is important, especially when data are scarce.
Open articleOncology
Varey AHR, Weitemeyer MB, Gjorup CA, Lo SN, Williams GJ, Thompson JF. Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis. Lancet Oncol 2026; 27: 452–60—In this Article, the PROSPERO registration number stated in the Summar
Open articleOncology
The 2026 G7 meeting of world leaders was held June 15–17 at Évian-les-Bains, Haute-Savoie, France, and hosted by President Emmanuel Macron of France. But among the usual high level political talks was a surprise announcement—a call to action on cancer. The leaders of the G7 natio
Open articleOncology
In June, 2026, a Working Group of 23 scientists from 13 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of butyl benzyl phthalate (BBzP), dibutyl phthalate (DBP), and diisononyl phthalate
Open articleOncology
Although substantial progress against cancer has been made by the USA over the past several decades, cancer-related disparities remain a crucial public health challenge in the country, suggests the Cancer Disparities Progress Report 2026, released by the American Association for
Open articleOncology
South Africa's completion of its first imPACT Review has raised hopes that long-standing gaps in cancer care could be translated into a new national cancer control plan, but clinicians and advocates caution that its value depends on whether it leads to funded implementation
Open articleOncology
The expansion of colorectal cancer screening in Ontario, Canada, has coincided with new evidence showing that registered First Nations people experience higher colon cancer incidence at younger ages and poorer survival after breast, cervical, and colon cancer diagnoses than other
Open articleOncology
Effective cancer control depends on the coordinated functioning of multiple interlocking systems, including regulation, workforce planning, research collaboration, supply chains, and clinical infrastructure. Disruption in any of these can have downstream consequences for cancer o
Open articleOncology
Trastuzumab rezetecan improved progression-free survival versus pyrotinib plus capecitabine and showed a distinct safety profile in patients with HER2-positive breast cancer, presenting as a potential new treatment option.
Open articleOncology
Switching to camizestrant plus CDK4/6 inhibitor at ESR1 mutation emergence, versus continuing aromatase inhibitor plus CDK4/6 inhibitor, resulted in sustained progression-free survival benefit that translated into a statistically significant improvement in second progression-free
Open articleOncology
The 5-year QOL findings showed worse chest wall toxicity and no effect on other QOL domains. The subgroup analyses suggested a potential negative effect of chemotherapy and axillary clearance after sentinel node biopsy.
Open articleOncology
A single, postoperative pirarubicin instillation after radical nephroureterectomy is an efficacious treatment with manageable adverse events to reduce recurrence in patients with upper tract urothelial carcinoma.
Open articleOncology
Cretostimogene showed clinically meaningful anti-tumour response, with an adverse event profile characterised predominantly by low-grade, transient events. Cretostimogene shows promise as an innovative bladder-sparing treatment for high-risk, BCG-unresponsive, non-muscle-invasive
Open articleOncology
In previously-treated patients with locally advanced or metastatic, radioactive iodine-refractory BRAFV600E-positive differentiated thyroid cancer, dabrafenib plus trametinib showed significant benefits for progression-free survival and overall response rate, with no new safety s
Open articleOncology
For MRI-defined, high-risk, locally advanced rectal cancer, the addition of irinotecan to standard of care did not improve outcomes and should not be used in combination with radiotherapy plus capecitabine.
Open articleOncology
In patients with dMMR or MSI-H locally advanced colorectal cancer, neoadjuvant toripalimab plus celecoxib significantly increased the proportion of patients attaining pathological complete response compared with toripalimab monotherapy, with a similar safety profile. These findin
Open articleOncology
Gastrectomy with cytoreductive surgery and HIPEC provided no survival benefit in patients with gastric cancer and limited peritoneal metastases compared with systemic therapy alone.
Open articleOncology
Baseline exposure to proton pump inhibitors and antibiotics was associated with inferior outcomes with durvalumab, but not with placebo, consistent with potential attenuation of the benefit of durvalumab with proton pump inhibitors and antibiotics in patients with unresectable st
Open articleOncology
A new drug for pancreatic cancer set ASCO abuzz this May, uniting the plenary hall in standing ovation—in a phase 3 trial, the RAS inhibitor daraxonrasib nearly doubled overall survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Pancreatic cancer is a l
Open articleOncology
Daraxonrasib—an oral RAS(ON) multiselective inhibitor—significantly improves survival compared with standard chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma, according to the phase 3 RASolute 302 trial. Eileen M O’Reilly and colleagues
Open articleOncology
The addition of ipilimumab to atezolizumab plus bevacizumab did not show any benefit in patients with previously untreated, unresectable hepatocellular carcinoma. These results do not support the addition of low-dose (1 mg/kg) ipilimumab to atezolizumab plus bevacizumab as a firs
Open articleOncology
Bladder cancer (LABC) after radical cystectomy (RC) is common, even with chemotherapy, and is associated with high morbidity and mortality. Therefore, this work aimed to investigate the effect and efficacy of adjuvant sandwich chemotherapy plus radiotherapy versus adjuvant chemot
Open articleOncology
Many older adults with cancer have at least one comorbidity. Type II diabetes mellitus (T2DM) is a common comorbidity among patients with prostate cancer (PC) and represents an important consideration in this population. Comorbid T2DM can negatively impact cancer-specific outcome
Open articleOncology
The primary objective of this study was to evaluate the efficacy of oral nutritional supplements (ONS) on chemotherapy tolerance and long-term survival outcomes in postoperative colorectal cancer patients undergoing chemotherapy. This study was a secondary analysis based on a ran
Open articleOncology
Patients with malignancy often have a poor prognosis and dismal quality of life. This study aimed to evaluate whether a combined nutrition, exercise, and psychological intervention could improve these outcomes. In an open-label, randomized controlled trial at the First Hospital o
Open articleOncology
The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of che
Open articleOncology
Locally advanced rectal cancer is routinely treated with neoadjuvant radiotherapy. Concomitant systemic anticancer therapy with standard fluoropyrimidines has not generally improved outcomes. Small studies reported high pathological complete response rates and acceptable toxicity
Open articleOncology
Active surveillance is noninferior to standard surgery for 2-year survival and improves short-term health-related quality of life among patients with a complete clinical response (CCR) after neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer. Although active surveillance
Open articleOncology
Talazoparib plus enzalutamide improved overall survival (OS) in the biomarker-unselected TALAPRO-2 population, but OS benefit was not statistically significant in the homologous recombination repair (HRR) non-deficient or unknown subgroup, whereas radiographic progression-free su
Open articleOncology
Neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer (LARC) is frequently delayed in resource-limited settings due to restricted access to radiotherapy. Total neoadjuvant therapy (TNT), which starts with chemotherapy, may offer a practical alternative. This ran
Open articleOncology
This study aimed to develop a dynamic-static combined Neiyanggong intervention for breast cancer patients undergoing chemotherapy and to evaluate its effectiveness in alleviating cancer-related fatigue, with sleep quality assessed as a secondary outcome. A single-center, parallel
Open articleOncology
Immune checkpoint blockade is minimally active in unselected castration-resistant prostate cancer (CRPC) and does not reproducibly yield durable decreases in prostate-specific antigen (PSA) levels. The Quick Efficacy Seeking Trial was designed to employ a combination of agents to
Open articleOncology
Background: Short-course radiotherapy (SCRT)-based total neoadjuvant therapy (TNT) is used for locally advanced rectal cancer (LARC). However, the pathological complete response (pCR) rate still hovers around 30%. Radiotherapy and immune checkpoint inhibitors have been shown to e
Open articleOncology
Current European expert consensus definitions for esophagogastric oligometastatic disease (OMD) primarily relate to adenocarcinoma. Oligometastatic esophageal squamous cell carcinoma (OMESQ) may require a distinct definition and treatment strategy. This systematic review and meta
Open articleOncology
To evaluate the feasibility and clinical value of a prostate cancer screening model incorporating total prostate-specific antigen (tPSA) and biparametric magnetic resonance imaging (bpMRI) in a Chinese population. Between May 2024 and May 2025, 2 251 men aged 50 years or older fr
Open articleOncology
Metastatic castration-resistant prostate cancer (mCRPC) is among the leading causes of cancer-related mortality in men worldwide. Treatment options for mCRPC typically include chemotherapy and androgen receptor pathway inhibitors. Immune checkpoint inhibitors (ICIs) have demonstr
Open articleOncology
The modest neoadjuvant response in early-stage HR+/HER2- breast cancer necessitates novel treatment intensification strategies. While radiotherapy can enhance systemic efficacy via immune modulation, the optimal fractionation for integration with immunochemotherapy remains unknow
Open articleOncology
Weight gain during prostate cancer treatment can worsen treatment-related side effects, impair quality of life, and increase risks of recurrence and prostate cancer-specific mortality. The Prostate Cancer Patient Empowerment Program (PC-PEP), a comprehensive, home-based 6-month d
Open articleOncology
Siglec-15 has emerged as a novel immune checkpoint molecule and a potential therapeutic target in solid tumors. Previous studies reported inconsistent prognostic significance of tumoral Siglec-15 expression across cancer types. We therefore conducted a systematic review and meta-
Open articleOncology
This systematic review with functional meta-synthesis and exploratory meta-analysis evaluated the clinical utility of molecular testing in ameloblastoma, focusing on diagnostic, genotype-phenotype, prognostic, liquid-biopsy, and precision-therapy implications. PubMed/MEDLINE, Sco
Open articleOncology
KRAS mutations are common in colorectal cancer, but the impact of KRAS mutation subtypes on treatment response remains poorly understood. This research aimed to investigate whether different KRAS mutations influence pathological complete response (pCR) rates after neoadjuvant che
Open articleOncology
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a high risk of early central nervous system dissemination and poor outcomes after brain metastasis (BM). This systematic review summarizes current evidence on incidence, treatment strategies, outcome
Open articleOncology
Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is increasingly prevalent and accounts for 22-70% of HNSCCs depending on the region. Although prophylactic HPV vaccines were approved in the early 2000s to prevent HPV infection and oncogenesis, t
Open articleOncology
To investigate the benefits of listening to pre-bedtime music on sleep quality and daytime sleepiness for family caregivers of palliative care patients at home. Multicenter, randomized controlled clinical trial. Seventy-six caregivers were randomly assigned to intervention (n = 3
Open articleOncology
Fecal microbiota transplantation (FMT) has shown promise in overcoming resistance to immune checkpoint inhibitors (ICIs) in early-phase cancer trials. We investigated the safety, feasibility and efficacy of FMT from ICI responders to patients with advanced cancers progressing on
Open articleOncology
Tenosynovial giant cell tumors (TGCT) are rare, locally aggressive neoplasms causing pain, stiffness, swelling, limited range of motion, and joint degeneration, which can be debilitating. Therapeutic options include surgery or systemic therapy with colony-stimulating factor 1 rec
Open articleOncology
Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoproliferative malignancies that predominantly affects older adults. Chemotherapy remains the primary modality of treatment for many NHL subtypes, yet it often brings about adverse effects such as myelosuppression, anem
Open articleOncology
The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of a cohort of patients with ovarian cancer (OC) wi
Open articleOncology
Adherence to oral anticancer medications (OAMs) is critical for clinical outcomes in breast cancer (BC), yet assessment methods lack standardization. The goal is to evaluate OAMs adherence in BC patients utilizing the most common adherence assessment methods on the same populatio
Open articleOncology
Cancer cells counteract oxidative stress through upregulation of antioxidant networks. Peroxiredoxin 3 (PRX3), a mitochondrial antioxidant enzyme, regulates reactive oxygen species homeostasis and promotes tumor cell survival. The natural compound thiostrepton (TS) covalently inh
Open articleOncology
This study aimed to determine the effect of listening to music during chemotherapy sessions on depression, anxiety, stress, and treatment-related symptoms. A randomised controlled trial was conducted between June and September 2023 with stable, non-metastatic patients receiving o
Open articleOncology
Anaplastic lymphoma kinase (ALK) inhibitors have emerged as promising agents for patients with resectable ALK-positive non-small-cell lung cancer (NSCLC). Whether ensartinib, a second-generation ALK inhibitor, is safe and effective in such patients is unknown. In this phase 3, do
Open articleOncology
Tetraspanin CD37, highly expressed in mature B-cells, represents an opportunity for therapeutic targeting in B-cell malignancies. GEN3009 (DuoHexaBody-CD37), a humanized biparatopic IgG1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overlapping CD37 e
Open articleOncology
Chemotherapy-induced diarrhea (CID) and constipation (CIC) are prevalent, distressing symptoms that can adversely affect nutritional status and treatment tolerance. Evidence for non-pharmacological management remains limited, particularly in low-resource settings. This pilot rand
Open articleOncology
The Belgian Precision initiative aims to implement tumor-agnostic next-generation sequencing (NGS) in patients with advanced cancer and expand genotype-matching drug availability. The present investigator-driven trial aimed to study the efficacy of afatinib in patients with advan
Open articleOncology
Paclitaxel is an effective chemotherapeutic agent for breast cancer, but its use is often limited by cumulative toxicities linked to mitochondrial dysfunction and oxidative stress. This study investigated whether Coenzyme Q10 (CoQ10) could mitigate paclitaxel-induced adverse even
Open articleOncology
Peptide receptor radionuclide and targeted therapy are both approved treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs), but clinical evidence for preferred sequencing is scarce. The COMPETE trial evaluated the efficacy and har
Open articleOncology
Dostarlimab+carboplatin-paclitaxel followed by dostarlimab maintenance demonstrated statistically significant and clinically meaningful benefits in progression-free and overall survival in the overall population of primary advanced/recurrent endometrial cancer versus chemotherapy
Open articleOncology
Peritoneal metastasis (PM) of gastric cancer (GC) is frequently resistant to systemic chemotherapy, which leads to a poor prognosis. This study was designed to compare the safety and tolerability of hyperthermic intraperitoneal chemotherapy (HIPEC) with recombinant mutant human t
Open articleOncology
Adjuvant pembrolizumab improves disease-free and overall survival among patients with resected clear-cell renal-cell carcinoma. The hypoxia-inducible factor 2α inhibitor belzutifan has activity in advanced disease. Adjuvant pembrolizumab with belzutifan may further improve outcom
Open articleOncology
Here we report long-term outcomes of adjuvant metronomic capecitabine in patients with locoregionally advanced nasopharyngeal carcinoma. In this multicenter, open-label, parallel-group, randomized, controlled, phase 3 trial, 406 patients who had completed definitive chemoradiothe
Open articleOncology
Brain metastases in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) frequently contribute to treatment failure. This phase II study aims to evaluate furmonertinib (160 mg daily) in 40 untreated patients with EGFR-mutant NSCLC and central nervous
Open articleOncology
Clear cell sarcoma (CCS) is an ultra-rare sarcoma with no established standard systemic therapy of proven efficacy. Mesenchymal-epithelial transition factor (MET) overexpression drives CCS progression and serves as a promising therapeutic target. Vebreltinib is a highly selective
Open articleOncology
Background: SYHX2011 is a novel albumin-bound paclitaxel, in which most nonparticulate human albumin is replaced with mannitol and sucrose. This study aimed to compare SYHX2011 and paclitaxel for injection (albumin-bound) (PAB) in patients with breast cancer. Methods: Patients wi
Open articleOncology
Chemotherapy-related cognitive impairment (CRCI) is a prevalent neurotoxicity in patients with breast cancer (BC), leading to cognitive decline and reduced quality of life. Exercise is recommended as a potential strategy to mitigate CRCI; however, optimal exercise modalities and
Open articleOncology
Premenopausal women receiving combination endocrine therapy often experience substantial declines in quality of life (QOL), cognitive functioning, and treatment adherence. The MyChoice study evaluated whether individualized behavioral and complementary interventions could help ma
Open articleOncology
It is controversial whether monotherapy with immunotherapeutics is effective in early-stage hepatocellular carcinoma (HCC). We evaluated immunotherapy monotherapy as an initial neoadjuvant strategy. This prospective, single-arm, phase II trial of an adaptive neoadjuvant strategy
Open articleOncology
Pegylated liposomal doxorubicin (PLD) is a potent immunogenic cell death inducer, allowing for improved tumor-immune recognition and T-cell activation. We report a phase Ib study of combined PLD and pembrolizumab (PEM) in estrogen receptor (ER)-positive/human epidermal growth fac
Open articleOncology
Microsatellite-stable (MSS) colorectal cancer (CRC), which accounts for approximately 85% of cases annually, has demonstrated limited responsiveness to immune checkpoint blockade in the metastatic setting. Circulating tumor DNA (ctDNA) enables sensitive detection of minimal resid
Open articleOncology
Predictive biomarkers for immune checkpoint inhibitors (ICIs) are largely identified retrospectively, but their prospective clinical utility remains unproven. Here, we report DUTRENEO, a prospective randomized phase 2 trial testing whether a retrospectively validated 18-gene bulk
Open articleOncology
The clinical efficacies of third- or later-line therapies for metastatic colorectal cancer (CRC) are extremely limited. The purpose of this study was to evaluate the safety and efficacy of a chimeric antigen receptor T (CAR T) cell targeting guanylyl cyclase 2C (GUCY2C) that was
Open articleOncology
Glioblastoma (GBM) is an immunologically cold brain tumor with poor outcome, characterized by a myeloid-driven immunosuppressive microenvironment. Here we report an interim analysis of a first-in-human phase 1/2a dose-escalation study evaluating Temferon-a genetically engineered
Open articleOncology
For patients with clinical stage III melanoma, a potentially surgically curable disease, neoadjuvant immunotherapy improves event-free survival. Substantial pathologic complete response (pCR) rates in the affected nodal basin have raised interest in response-directed care includi
Open articleOncology
Preoperative immuno-chemotherapy improves outcomes in triple-negative breast cancer, but associated imaging response patterns remain poorly characterized. This study aimed to describe a novel MRI phenomenon, tumor flare-like response (TFLR), and evaluate its association with path
Open articleOncology
The appropriateness of concurrent chemoradiotherapy (cCRT) for older or clinically vulnerable stage III unresectable non-small-cell lung cancer (NSCLC) patients remains contentious. Furthermore, the survival implications of de-escalating thoracic radiotherapy (RT) intensity in th
Open articleOncology
Checkpoint inhibitor immunotherapy (CPI) for BRAF mutant advanced melanoma first-line results in a better long-term survival compared to targeted therapy (TT), however TT induction may benefit poor prognosis groups. The parallel-arm, randomised phase II, multicentre, feasibility
Open articleOncology
BACKGROUNDMinimally invasive biomarkers predicting the immunotherapy response in head and neck squamous cell carcinoma (HNSCC) remain an unmet clinical need.METHODSIn a prospective, multi-institutional phase II trial, we performed whole-genome sequencing of 185 longitudinal plasm
Open articleOncology
Docetaxel plus ramucirumab is a standard second-line treatment for advanced non-small cell lung cancer (NSCLC). Prior immunotherapy has been suggested to potentially affect the efficacy of subsequent docetaxel plus ramucirumab, but prospective evidence is limited. This multicente
Open articleOncology
We previously reported results from a randomized phase 2 trial evaluating a DNA vaccine (pTVG-HP) encoding prostatic acid phosphatase (PAP) versus placebo (GM-CSF vaccine adjuvant alone) in patients with PSA-recurrent, nonmetastatic, noncastrate prostate cancer (NCT01341652). The
Open articleOncology
Selecting appropriate anesthetic agents and techniques that ensure hemodynamic stability and attenuate perioperative stress responses is crucial for ovarian cancer surgery. This study aimed to evaluate the effects of etomidate combined with transversus abdominis plane block (TAPB
Open articleOncology
The clinical efficacy and immune modulation of neoadjuvant immunochemotherapy for epithelial ovarian cancer (EOC) remain uncertain. To clarify these effects, the NAIVE trial (NCT04815408), a prospective phase II study, evaluated the efficacy of neoadjuvant platinum-based chemothe
Open articleOncology
In line with current guidelines, risk stratification in papillary thyroid microcarcinoma (PTMC) has shifted from simple diameter-based assessments to evaluation of individual tumor biology. Therefore, this study aimed to investigate how baseline clinical and molecular risk factor
Open articleOncology
Several RET-targeted agents, including highly selective RET inhibitors (SRIs) and multi-kinase inhibitors (MKIs), have been approved for the treatment of advanced medullary thyroid cancer (MTC). Despite these agents targeting the same pathway, direct comparative data is lacking.
Open articleOncology
The Systemic Immune-Inflammation Index (SII), a composite biomarker integrating neutrophil, platelet, and lymphocyte counts, has been increasingly investigated in thyroid cancer. However, its diagnostic accuracy and association with lymph node metastasis (LNM) remain uncertain. T
Open articleOncology
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have demonstrated clinical benefit in early-stage breast cancer (eBC), enhancing antitumor immune responses. However, their incorporation into perioperative polychemotherapy has introduced new concerns regarding sa
Open articleOncology
Ectopic thyroid carcinoma (ETC) is a rare malignancy for which standardized treatment guidelines remain unavailable. This systematic review aimed to comprehensively characterize the clinical features, treatment patterns, outcomes, and prognostic factors of ETC using the largest c
Open articleOncology
To systematically evaluate the diagnostic value of fine-needle aspiration cytology (FNAC) and fine-needle aspirate calcitonin (FNA-CT) measurement in medullary thyroid carcinoma (MTC). This study has been registered in the International Prospective Register of Systematic Reviews
Open articleOncology
Differentiated thyroid carcinoma (DTC) is traditionally treated with total thyroidectomy (TT); however, hemithyroidectomy (HT) has been increasingly used. Previous analyses on DTC recurrence rate with HT and TT have yielded inconsistent results; this study aimed to bridge this ga
Open articleOncology
This study aimed to identify the clinical and sociodemographic risk factors and compare cancer stage, treatment, and survival outcomes associated with ovarian cancer diagnosed following an emergency presentation versus other routes. A systematic search of Embase and MEDLINE was c
Open articleOncology
Prostate cancer (PCa) is the most common nonskin cancer among men. Although treatments achieve excellent survival for localized PCa, long-lasting complications significantly diminish patients' quality of life (QOL) across physical, sexual, psychosocial, and general symptom d
Open articleOncology
The purpose of this trial was to assess the feasibility, acceptability and safety of a 10-week hybrid (in-clinic and virtual) resistance exercise training RET program with or without CrM in individuals treated for colorectal cancer. Twenty-seven participants were randomized to RE
Open articleOncology
The optimal radiation dose for definitive chemoradiotherapy in locally advanced unresectable esophageal squamous cell carcinoma (ESCC) remains controversial, particularly whether dose escalation can overcome treatment resistance. We previously reported that escalation to 60 Gy in
Open articleOncology
Second-line treatment for metastatic colorectal cancer (mCRC) typically involves oxaliplatin- or irinotecan-based doublet chemotherapy with or without anti-angiogenic antibodies. Triplet regimens such as FOLFOXIRI have demonstrated synergy and improved efficacy as first-line ther
Open articleOncology
This protocol describes a randomized, open-label, assessor-blinded clinical workflow for evaluating modified San'ao Decoction and Erchen Decoction combined with camrelizumab and anlotinib in patients with advanced esophageal squamous cell carcinoma presenting with esophageal
Open articleOncology
This study aimed to refine estimates of lenvatinib plus pembrolizumab (Len/Pembro) efficacy in East Asian patients with advanced renal cell carcinoma (aRCC) in the CLEAR trial using Bayesian borrowing from Western Europe and North America (WENA), and to assess safety while preser
Open articleOncology
IntroductionThere is currently no biomarker for progression-free survival (PFS) for patients undergoing treatment for metastatic renal cell carcinoma (RCC). The aim of our study was to evaluate computed tomography perfusion (CTp) blood flow as an early marker of PFS in patients w
Open articleOncology
Prediction models for postoperative recurrence in papillary thyroid carcinoma (PTC) have increased substantially in recent years. However, recurrence outcomes are inconsistently defined across studies, particularly with respect to structural and biochemical recurrence, and the qu
Open articleOncology
Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites
Open articleOncology
The objective of this study is to explore effects on self-reported fatigue at 4 weeks and 12 months after surgery in patients with colorectal cancer undergoing a pre- and postoperative exercise intervention compared to standard care in a randomized trial. Fatigue after cancer sur
Open articleOncology
Post-treatment colorectal cancer patients commonly experience cancer-related fatigue (CRF), yet few interventions address this concern. To examine the feasibility, acceptability, and preliminary effects of a psycho-behavioural intervention on CRF and other health outcomes in this
Open articleOncology
Fatigue is a common debilitating symptom of breast cancer (BC), and its treatment may result in a significant symptom burden and affect adherence to treatment. Graded exercise therapy (GET) and cognitive behavioral therapy (CBT) have separately been shown in previous studies to b
Open articleOncology
Post-mortem tissue donation (PTD) is increasingly recognised as an important resource for advancing cancer research. Developing effective recruitment strategies for PTD programs requires a thorough understanding of interest-holder perspectives, which remain insufficiently explore
Open articleOncology
Population pharmacokinetic (PK) and exposure-response analyses were performed to characterize the PK and exposure-response relationships of vepdegestrant, a first-in-class, oral PROteolysis-TArgeting Chimera estrogen receptor degrader. Population PK and exposure-response analyses
Open articleOncology
Benign prostatic hyperplasia (BPH) is a condition that impairs the quality of life and occurs with high frequency in older men. Prostate cancer is one of the most common malignancies in men, characterized by high mortality rates. The aim of the study was to systematize data on th
Open articleOncology
In the Original Investigation titled “Hospital Adoption and Pricing for Oncology Biosimilars” published online March 11, 2026, how Medicare marks up acquisition of oncology biosimilars compared with biologics was adjusted in the article’s Discussion section. This was corrected on
Open articleOncology
To the Editor We wish to express several concerns regarding the article on hospital adoption and pricing for oncology biosimilars. First, we disagree with the statement that “Medicare bases its reimbursement for biosimilars on the high acquisition price for the biologic, not the
Open articleOncology
In Reply I thank Drs Jensen and Tichy for the opportunity to respond to the comments on our article on hospital adoption and pricing for oncology biosimilars. Their comments are factually correct and add insight into the complex process of drug payment and strengthen the core mes
Open articleOncology
To evaluate whether oral cryotherapy (OC) using ice-cold saline reduces the incidence and severity of high-dose methotrexate (HD-MTX)-induced oral mucositis (OM) in children with acute lymphoblastic leukemia (ALL). This single-center, open-label, parallel-group randomized control
Open articleOncology
Docetaxel (DTX) is commonly employed in patients with castration-resistant prostate cancer (CRPC) following failure of androgen receptor signaling inhibitors (ARSIs). However, the impact of prior ARSI treatment on the efficacy of subsequent DTX therapy remains unclear. This study
Open articleOncology
To evaluate the effect of Bach Flower Remedies Therapy on the hope and quality of life of people with advanced cancer. Randomized, triple-blind (1:1) clinical trial in a high-complexity public hospital in the Southern region of Brazil. Ninety-nine participants were allocated to e
Open articleOncology
The gut microbiome is increasingly recognized as a central factor in carcinogenesis. Dietary components and therapeutic interventions, including probiotics, may influence microbial composition and function, thereby modulating cancer risk. Del-Immune V, a metabiotic supplement der
Open articleOncology
Objective: To investigate the effects of early postoperative enteral nutrition on nutritional status, immune function, and postoperative recovery in breast cancer patients receiving neoadjuvant therapy. Methods: A total of 90 breast cancer patients who underwent neoadjuvant thera
Open articleOncology
This study systematically evaluates the impact of the initiation time of postoperative chemotherapy on overall survival (OS) in patients with colorectal cancer, providing evidence to guide clinical decisions on chemotherapy timing. Following PRISMA and MOOSE guidelines, PubMed, E
Open articleOncology
This study aims to assess the dose-response relationship between different exercise modalities and sleep quality in breast cancer survivors who have completed their primary treatment, and to propose evidence-based exercise prescriptions for clinical practice. Bayesian network and
Open articleOncology
Introduction Breast cancer survivors (BCS) often experience side effects such as the fatigue, sleep disturbance and depression symptom cluster (FSDSC). Previous studies have demonstrated the potential efficacy of Tai Chi (TC) for improving FSDSC in BCS in a hospital setting in Ch
Open articleOncology
Objectives To investigate the association between exposure to specific endocrine-disrupting chemicals (EDCs), air pollutants and the risk of localised prostate cancer (PCa) and to evaluate the combined effect of mixed EDC exposures. Design A case–control study. Setting Secondary
Open article